Art. -Nr.: HY-16743A

Ibiglustat (L-Malic acid)

(Synonyms: Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid))

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.65%
CAS. Nr.: 1629063-78-0
Formel: C₂₄H₃₀FN₃O₇S
Molecular Weight:523.57

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ibiglustat (L-Malic acid) Chemical Structure

CAS. Nr.: 1629063-78-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Glucosylceramide synthase^[1].

In Vitro

Ibiglustat (SAR402671) (1 μM, 15 days) L-Malic acid treated Fabry disease (FD) cells are close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat L-Malic acid can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 1629063-78-0
Appearance Solid
Molecular Weight 523.57
Formel C₂₄H₃₀FN₃O₇S
Color White to off-white
SMILES

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C.OC(C[C@H](O)C(O)=O)=O
Synonyms

Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All Cell Proliferation/Viability AssayFlow CytometryWBIFHistological Imaging/Staining

Sort by:

Journal Impact Factor

Int J Biol Macromol

Inhibiting UGCG prevents PRV infection by decreasing lysosome-associated autophage. [Abstract]

2025 Jan:285:138303. PMID: 39631580

Ibiglustat (L-Malic acid) purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:285:138303. [Abstract]

CCK-8 assay evaluating the proliferation of PK-15 cells treated with UGCG inhibitors Ibiglustat (1.6-1000 nM) over 12-36 h.

Ibiglustat (L-Malic acid) purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:285:138303. [Abstract]

Flow cytometry analysis of PRV-GFP infection in PK-15 cells pretreated with UGCG inhibitors Eliglustat hemitartrate (1.6–1000 nM) and Ibiglustat (1.6–1000 nM) for 3 h, followed by GFP fluorescence intensity measurement 24 h post-infection to assess viral replication. The results showed that Ibiglustat significantly reduced PRV-GFP fluorescence signals in a dose-dependent manner.

Ibiglustat (L-Malic acid) purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:285:138303. [Abstract]

Ibiglustat (1.6–1000 nM; pretreated 3 h) reduced PRV-gB protein levels in a dose-dependent manner in PRV-QXX-infected PK-15 cells.

Ibiglustat (L-Malic acid) purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:285:138303. [Abstract]

Ibiglustat (1.6–1000 nM; 3 h) reduced PRV-gB protein levels in a dose-dependent manner in PRV-QXX-infected PK-15 cells.

Ibiglustat (L-Malic acid) purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2025 Jan:285:138303. [Abstract]

Brain, lung, liver, and spleen injury were assessed using hematoxylin and eosin staining 3 days post-infection (n = 3 per group). Histopathological examination revealed that PRV infection in mice induced proliferation of brain microglial cells, inflammatory cell infiltration in the lungs, significant thickening of alveolar septa, vacuolar degeneration of liver cells, and inflammatory tissue damage in the spleen. These pathological changes were attenuated by treatment with the UGCG inhibitors, Eliglustat hemitartrate or Ibiglustat ((2.5 mg/kg); s.c.; once daily for the first 3 days of PRV infection). Scale bar = 50 μm.
FASEB J

Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin-induced colon epithelial cell signaling. [Abstract]

2020 Dec;34(12):15922-15945. PMID: 33047400
bioRxiv

2024 Jan 29.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (191.00 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9100 mL

9.5498 mL

19.0996 mL

5 mM

0.3820 mL

1.9100 mL

3.8199 mL

10 mM

0.1910 mL

0.9550 mL

1.9100 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22. [Content Brief]

[2]. Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86-98. [Content Brief]

[3]. Iva Stojkovska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2017.

[4]. Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9100 mL	9.5498 mL	19.0996 mL	47.7491 mL
	5 mM	0.3820 mL	1.9100 mL	3.8199 mL	9.5498 mL
	10 mM	0.1910 mL	0.9550 mL	1.9100 mL	4.7749 mL
	15 mM	0.1273 mL	0.6367 mL	1.2733 mL	3.1833 mL
	20 mM	0.0955 mL	0.4775 mL	0.9550 mL	2.3875 mL
	25 mM	0.0764 mL	0.3820 mL	0.7640 mL	1.9100 mL
	30 mM	0.0637 mL	0.3183 mL	0.6367 mL	1.5916 mL
	40 mM	0.0477 mL	0.2387 mL	0.4775 mL	1.1937 mL
	50 mM	0.0382 mL	0.1910 mL	0.3820 mL	0.9550 mL
	60 mM	0.0318 mL	0.1592 mL	0.3183 mL	0.7958 mL
	80 mM	0.0239 mL	0.1194 mL	0.2387 mL	0.5969 mL
	100 mM	0.0191 mL	0.0955 mL	0.1910 mL	0.4775 mL

Bioz

Keywords

Ibiglustat (L-Malic acid)

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Ibiglustat (L-Malic acid)

Ibiglustat

Miglustat hydrochloride

Eliglustat

Miglustat

Eliglustat hemitartrate

DL-threo-PDMP hydrochloride

Miglustat hydrochloride (Standard)

Eliglustat (Standard)

Miglustat (Standard)

Lucerastat

Glucosylceramide synthase-IN-2

TP-060

Publications Citing Use of MedChemExpress (MCE) Ibiglustat (L-Malic acid)

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Ibiglustat (L-Malic acid)

Ibiglustat

Miglustat hydrochloride

Eliglustat

Miglustat

Eliglustat hemitartrate

DL-threo-PDMP hydrochloride

Miglustat hydrochloride (Standard)

Eliglustat (Standard)

Miglustat (Standard)

Lucerastat

Glucosylceramide synthase-IN-2

TP-060

Publications Citing Use of MedChemExpress (MCE) Ibiglustat (L-Malic acid)

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Ibiglustat (L-Malic acid) Related Classifications

HY-16743A Related Classifications

Bioz